Phase IIa, Randomised, Controlled, OpenLabel Trial of Rosuvastatin for the Prevention of AminoglycosideInduced Kidney Toxicity in Children with Cystic Fibrosis

Trial Profile

Phase IIa, Randomised, Controlled, OpenLabel Trial of Rosuvastatin for the Prevention of AminoglycosideInduced Kidney Toxicity in Children with Cystic Fibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Kidney disorders
  • Focus Pharmacodynamics
  • Acronyms PROteKT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Sep 2016 Status changed from recruiting to completed.
    • 28 Jan 2016 Accrual to date is 36% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top